Should PD-L1 Expression Be Used As A Biomarker For Immunotherapy?
Executive Summary
Oncologists’ distrust of the PD-L1 biomarker was more evident at ASCO than ever. Regardless of what “marketing people” might want, immunotherapy demands more than a single biomarker, MD Anderson GU specialist Padmanee Sharma tells a packed audience on opening day. >>>Listen in to an audio clip of Genentech’s Ira Mellman discussing the company’s view.